Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Attorney Richard Cassin On FCPA’s Impact On Foreign Acquisitions And Competitor Snitching: An Interview With PharmAsia News

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmaceutical companies face stepped up scrutiny of acquisitions and the possibility that competitors will point fingers at suspected fraud in order to lessen their own enforcement actions and penalties.

Advertisement

Related Content

A Long Way Still For Corrupt Business Practices In China, India - Pharmaceutical Regulatory And Compliance Congress
Foreign Corrupt Practices Act Raises Disclosure Dilemma For Internal Investigations
J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe
U.S. Regulators Beef Up Investigation of Corporate Bribery & Corruption Overseas

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel